MAPT and Alzheimer disease: Mitophagy-dependent signaling is reported to not only reduce Aβ and tau pathology (Pan et al., 2021), but also alleviate cognitive damages (Fang et al., 2019; Pan et al., 2021) through AMPK and SIRT1 activation, mTOR inhibition, and lysosomal functional improvement in AD progression (Fang et al., 2019).